Ariad Pharma Soars on Positive Drug News

ARIAD Pharmaceuticals, Inc. (ARIA) continues to climb higher midday, printing a fresh 52-week high above $6.90 level. Early Tuesday, the Cambridge, Mass.- based firm reported positive Phase III clinical data for its ridaforolimus drug to target cancerous tumors of the soft tissue or bone. Ariad said ridaforolimus met “the primary endpoint of improved progression-free survival [...]